Table 5.
Distribution of patients based on most relevant clinical and pathological parameters in (A) TCGA series, (B) Our series.
| Stage | Endometrioid | Serous | |||
|---|---|---|---|---|---|
| Grade 1 | Grade 2 | Grade 3 | All | Total | |
| (A) | |||||
| I | 78 (23) | 83 (24) | 70 (21) | 17 (5) | 248 (73) |
| II | 3 (1) | 9 (3) | 6 (2) | 5 (1) | 23 (7) |
| III | 7 (2) | 12 (4) | 26 (8) | 25 (7) | 70 (21) |
| Adjuvant therapy | |||||
| RT | 12 (3) | 28 (8) | 22 (6) | 7 (2) | 69 (19) |
| Chemo | 2 (1) | 6 (2) | 14 (4) | 13 (4) | 35 (10) |
| ChemoRT | 2 (1) | 9 (3) | 18 (5) | 17 (5) | 46 (13) |
| Unknown | 70 (20) | 61 (17) | 57 (16) | 16 (5) | 204 (58) |
| Total | 86 (24) | 104 (29) | 111 (31) | 53 (15) | 354 (100) |
| (B) | |||||
| I | 40 (42) | 24 (25) | 6 (6) | 7 (7) | 77 (80) |
| II | 0 (0) | 1 (1) | 0 (0) | 1 (1) | 2 (2) |
| III | 5 (5) | 3 (3) | 4 (4) | 5 (5) | 17 (18) |
| Adjuvant therapy | |||||
| RT | 21 (22) | 8 (8) | 2 (2) | 1 (1) | 32 (33) |
| Chemo | 2 (2) | 1 (1) | 2 (2) | 7 (7) | 12 (13) |
| ChemoRT | 3 (3) | 3 (3) | 6 (6) | 3 (3) | 15 (16) |
| Unknown | 2 (2) | 1 (1) | 0 (0) | 2 (2) | 5 (5) |
| Total | 28 (29) | 13 (13) | 10 (10) | 13 (13) | 64 (67) |
| 32 (33) patients did not receive any treatment | |||||
| Median follow-up (months) | 34.45 (1.8–91.2) | ||||
| Median PFS (months) | 33.1 (1.87–91.2) | ||||
| Median OS (months) | 34.45 (1.87–91.2) | ||||
| Relapse (%) | 14.6 | ||||
| Exitus (%) | 11.4 | ||||